421-430 of 3,661 results

  • Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor

    Feature

    This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.

  • Medicaid State Fact Sheets

    Feature

    What percentage of people are covered by Medicaid in your state? Our State Medicaid fact sheets provide a snapshot with key data for Medicaid in every state related to current coverage, access, and financing, as well as a politics section for each state.

  • The Efficacy of a New Long-Acting Injectable PrEP

    Quick Insights

    The news today about the efficacy of a new long-acting injectable PrEP, the second such breakthrough announcement in recent months, is nothing short of groundbreaking.

  • Understanding Fraud and Abuse in Medicaid

    Event Date:
    Event

    As Congress considers ways to help pay for extending tax cuts, some lawmakers have suggested that hundreds of billions of dollars in federal savings could be achieved by addressing fraud, waste and abuse in the Medicaid program. Three experts joined Health Wonk Shop series moderator Larry Levitt in an hour-long discussion designed to unpack claims about fraud and abuse and put them in a larger context.

  • The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation

    Issue Brief

    The Medicare drug price negotiation program could improve coverage of drugs selected for negotiation for Medicare beneficiaries because the law requires all Medicare Part D plans to cover each of the selected drugs, including all dosages and forms, when negotiated prices take effect. This analysis examines 2026 Medicare Part D formulary coverage of drugs selected for negotiation to measure the effect of the IRA's coverage requirement.